These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38698580)

  • 61. Lack of plasma prolactin response to intravenously injected vasoactive intestinal polypeptide in patients with prolactin-secreting adenoma.
    Kaji H; Chihara K; Kita T; Kashio Y; Okimura Y; Fujita T
    Acta Endocrinol (Copenh); 1985 Dec; 110(4):445-50. PubMed ID: 4090907
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Reduced Growth Hormone Secretion is Associated with Nonalcoholic Fatty Liver Disease in Obese Children.
    Liang S; Yu Z; Song X; Wang Y; Li M; Xue J
    Horm Metab Res; 2018 Mar; 50(3):250-256. PubMed ID: 29341046
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Subclinical hypothyroidism as a risk factor for the development of cardiovascular disease in obese adolescents with nonalcoholic fatty liver disease.
    Sert A; Pirgon O; Aypar E; Yilmaz H; Odabas D
    Pediatr Cardiol; 2013 Jun; 34(5):1166-74. PubMed ID: 23344895
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Risk of obstructive sleep apnea with daytime sleepiness is associated with liver damage in non-morbidly obese patients with nonalcoholic fatty liver disease.
    Pulixi EA; Tobaldini E; Battezzati PM; D'Ingianna P; Borroni V; Fracanzani AL; Maggioni M; Pelusi S; Bulgheroni M; Zuin M; Fargion S; Montano N; Valenti L
    PLoS One; 2014; 9(4):e96349. PubMed ID: 24763757
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Paeoniflorin ameliorates antipsychotic-induced hyperprolactinemia in rats by attenuating impairment of the dopamine D2 receptor and TGF-β1 signaling pathways in the hypothalamus and pituitary.
    Huang X; Ren L; Hou L; Fan H; Wang C; Wang C; Li Y
    J Ethnopharmacol; 2020 Jul; 257():112862. PubMed ID: 32294507
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Paeoniflorin and liquiritin, two major constituents in Chinese herbal formulas used to treat hyperprolactinemia-associated disorders, inhibits prolactin secretion in prolactinoma cells by different mechanisms.
    Wei Y; La L; Wang L; Batey R; Wang C; Li Y
    J Ethnopharmacol; 2017 May; 204():36-44. PubMed ID: 28396166
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prolactin improves hepatic steatosis via CD36 pathway.
    Zhang P; Ge Z; Wang H; Feng W; Sun X; Chu X; Jiang C; Wang Y; Zhu D; Bi Y
    J Hepatol; 2018 Jun; 68(6):1247-1255. PubMed ID: 29452209
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy.
    Wang L; Wang X; Gong F; Pan H; Zhu H
    Front Endocrinol (Lausanne); 2023; 14():1285477. PubMed ID: 38093965
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Serum Pentraxin 3 Fragment as a Noninvasive Marker of Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents.
    Hamza RT; Elfaramawy AA; Mahmoud NH
    Horm Res Paediatr; 2016; 86(1):11-20. PubMed ID: 27309736
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Hyperprolactinemia in Children with Subclinical Hypothyroidism.
    Sharma N; Dutta D; Sharma LK
    J Clin Res Pediatr Endocrinol; 2017 Dec; 9(4):350-354. PubMed ID: 28529200
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Docosahexaenoic acid and non-alcoholic fatty liver disease in obese children: a novel approach?
    Verduci E; Lassandro C; Radaelli G; Soldati L
    J Transl Med; 2015 Apr; 13():109. PubMed ID: 25889212
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Macroprolactinemia: new insights in hyperprolactinemia.
    Kasum M; Oreskovic S; Zec I; Jezek D; Tomic V; Gall V; Adzic G
    Biochem Med (Zagreb); 2012; 22(2):171-9. PubMed ID: 22838183
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hyperprolactinemia and hypogonadism in the human female.
    Rolland R; Corbey RS
    Eur J Obstet Gynecol Reprod Biol; 1977; 7(5):337-48. PubMed ID: 400856
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Primary empty sella, galactorrhea, hyperprolactinemia and renal tubular acidosis.
    Bar RS; Mazzaferri EL; Malarkey WB
    Am J Med; 1975 Dec; 59(6):863-6. PubMed ID: 1190258
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?
    Targher G; Rossini M; Lonardo A
    Endocrine; 2016 Feb; 51(2):211-21. PubMed ID: 26024975
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases.
    Akkaya C; Kaya B; Kotan Z; Sarandol A; Ersoy C; Kirli S
    J Psychopharmacol; 2009 Aug; 23(6):723-6. PubMed ID: 18562408
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease.
    Nobili V; Donati B; Panera N; Vongsakulyanon A; Alisi A; Dallapiccola B; Valenti L
    J Pediatr Gastroenterol Nutr; 2014 May; 58(5):632-6. PubMed ID: 24345846
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.
    Qadri S; Ahlholm N; Lønsmann I; Pellegrini P; Poikola A; Luukkonen PK; Porthan K; Juuti A; Sammalkorpi H; Penttilä AK; D'Ambrosio R; Soardo G; Leeming DJ; Karsdal M; Arola J; Kechagias S; Pelusi S; Ekstedt M; Valenti L; Hagström H; Yki-Järvinen H
    J Clin Endocrinol Metab; 2022 Apr; 107(5):e2008-e2020. PubMed ID: 34971370
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [The pulsatile LH fluctuation (spiking) dependent on the circulating prolactin. Studies during physiological (puerperium), functional pathological and TRH induced hyperprolactinemia].
    Bohnet HG; Wiest HJ; Dahlén HG; Schneider HP
    Endokrinologie; 1975 Nov; 66(2):158-72. PubMed ID: 819256
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Reply to Mirrakhimov and Mirrakhimov--nonalcoholic fatty liver disease and cardiovascular risk in obese children and adolescents.
    Alp H
    Can J Cardiol; 2013 Sep; 29(9):1139.e9. PubMed ID: 23352427
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.